220 related articles for article (PubMed ID: 16252234)
1. Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.
Pasmooij AM; Pas HH; Deviaene FC; Nijenhuis M; Jonkman MF
Am J Hum Genet; 2005 Nov; 77(5):727-40. PubMed ID: 16252234
[TBL] [Abstract][Full Text] [Related]
2. Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations.
Pasmooij AM; Nijenhuis M; Brander R; Jonkman MF
J Invest Dermatol; 2012 May; 132(5):1374-83. PubMed ID: 22318390
[TBL] [Abstract][Full Text] [Related]
3. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion.
Jonkman MF; Scheffer H; Stulp R; Pas HH; Nijenhuis M; Heeres K; Owaribe K; Pulkkinen L; Uitto J
Cell; 1997 Feb; 88(4):543-51. PubMed ID: 9038345
[TBL] [Abstract][Full Text] [Related]
4. Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.
Pasmooij AM; Pas HH; Bolling MC; Jonkman MF
J Clin Invest; 2007 May; 117(5):1240-8. PubMed ID: 17476356
[TBL] [Abstract][Full Text] [Related]
5. A "late-but-fitter revertant cell" explains the high frequency of revertant mosaicism in epidermolysis bullosa.
van den Akker PC; Pasmooij AMG; Joenje H; Hofstra RMW; Te Meerman GJ; Jonkman MF
PLoS One; 2018; 13(2):e0192994. PubMed ID: 29470523
[TBL] [Abstract][Full Text] [Related]
6. Pigmentation and melanocyte supply to the epidermis depend on type XVII collagen.
Gostyński A; Pasmooij AM; Del Rio M; Diercks GF; Pas HH; Jonkman MF
Exp Dermatol; 2014 Feb; 23(2):130-2. PubMed ID: 24330315
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Novel COL17A1 Compound Heterozygous Mutation in a Chinese Girl with Non-Herlitz Junctional Epidermolysis Bullosa.
Yao YY; Zhang Y; Xie XH; Chen L; Zhu F; Zhou M
Curr Med Sci; 2020 Aug; 40(4):795-800. PubMed ID: 32862392
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the COL17A1 in non-Herlitz junctional epidermolysis bullosa and amelogenesis imperfecta.
Nakamura H; Sawamura D; Goto M; Nakamura H; Kida M; Ariga T; Sakiyama Y; Tomizawa K; Mitsui H; Tamaki K; Shimizu H
Int J Mol Med; 2006 Aug; 18(2):333-7. PubMed ID: 16820943
[TBL] [Abstract][Full Text] [Related]
9. Cycloheximide facilitates the identification of aberrant transcripts resulting from a novel splice-site mutation in COL17A1 in a patient with generalized atrophic benign epidermolysis bullosa.
Darling TN; Yee C; Koh B; McGrath JA; Bauer JW; Uitto J; Hintner H; Yancey KB
J Invest Dermatol; 1998 Feb; 110(2):165-9. PubMed ID: 9457913
[TBL] [Abstract][Full Text] [Related]
10. Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa.
Umegaki-Arao N; Pasmooij AM; Itoh M; Cerise JE; Guo Z; Levy B; Gostyński A; Rothman LR; Jonkman MF; Christiano AM
Sci Transl Med; 2014 Nov; 6(264):264ra164. PubMed ID: 25429057
[TBL] [Abstract][Full Text] [Related]
11. Type XVII collagen gene mutations in junctional epidermolysis bullosa and prospects for gene therapy.
Bauer JW; Lanschuetzer C
Clin Exp Dermatol; 2003 Jan; 28(1):53-60. PubMed ID: 12558632
[TBL] [Abstract][Full Text] [Related]
12. Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation.
Darling TN; Yee C; Bauer JW; Hintner H; Yancey KB
J Clin Invest; 1999 May; 103(10):1371-7. PubMed ID: 10330419
[TBL] [Abstract][Full Text] [Related]
13. Features of epidermolysis bullosa simplex due to mutations in the ectodomain of type XVII collagen.
Pasmooij AM; van der Steege G; Pas HH; Smitt JH; Nijenhuis AM; Zuiderveen J; Jonkman MF
Br J Dermatol; 2004 Sep; 151(3):669-74. PubMed ID: 15377356
[TBL] [Abstract][Full Text] [Related]
14. Autosomal dominant junctional epidermolysis bullosa.
Almaani N; Liu L; Dopping-Hepenstal PJ; Lovell PA; Lai-Cheong JE; Graham RM; Mellerio JE; McGrath JA
Br J Dermatol; 2009 May; 160(5):1094-7. PubMed ID: 19120338
[TBL] [Abstract][Full Text] [Related]
15. Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa.
Pasmooij AM; Garcia M; Escamez MJ; Nijenhuis AM; Azon A; Cuadrado-Corrales N; Jonkman MF; Del Rio M
J Invest Dermatol; 2010 Oct; 130(10):2407-11. PubMed ID: 20574443
[TBL] [Abstract][Full Text] [Related]
16. Oral steroid improves bullous pemphigoid-like clinical manifestations in non-Herlitz junctional epidermolysis bullosa with COL17A1 mutation.
Mabuchi E; Umegaki N; Murota H; Nakamura T; Tamai K; Katayama I
Br J Dermatol; 2007 Sep; 157(3):596-8. PubMed ID: 17596158
[TBL] [Abstract][Full Text] [Related]
17. Collagen XVII.
Has C; Kern JS
Dermatol Clin; 2010 Jan; 28(1):61-6. PubMed ID: 19945617
[TBL] [Abstract][Full Text] [Related]
18. Deletion of the cytoplasmatic domain of BP180/collagen XVII causes a phenotype with predominant features of epidermolysis bullosa simplex.
Huber M; Floeth M; Borradori L; Schäcke H; Rugg EL; Lane EB; Frenk E; Hohl D; Bruckner-Tuderman L
J Invest Dermatol; 2002 Jan; 118(1):185-92. PubMed ID: 11851893
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosa.
Kiritsi D; Kern JS; Schumann H; Kohlhase J; Has C; Bruckner-Tuderman L
J Med Genet; 2011 Jul; 48(7):450-7. PubMed ID: 21357940
[TBL] [Abstract][Full Text] [Related]
20. A very mild form of non-Herlitz junctional epidermolysis bullosa: BP180 rescue by outsplicing of mutated exon 30 coding for the COL15 domain.
Pasmooij AM; van Zalen S; Nijenhuis AM; Kloosterhuis AJ; Zuiderveen J; Jonkman MF; Pas HH
Exp Dermatol; 2004 Feb; 13(2):125-8. PubMed ID: 15009107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
